 | Up a level |
Journal Article
Zeyen, Thomas, Potthoff, Anna-Laura, Nemeth, Robert, Heiland, Dieter H., Burger, Michael C., Steinbach, Joachim P., Hau, Peter, Tabatabai, Ghazaleh, Glas, Martin, Schlegel, Uwe, Grauer, Oliver, Krex, Dietmar, Schnell, Oliver, Goldbrunner, Roland, Sabel, Michael 
ORCID: 0009-0000-1485-7820, Thon, Niklas, Delev, Daniel, Clusmann, Hans, Seidel, Clemens, Gueresir, Erdem, Schmid, Matthias ORCID: 0000-0002-0788-0317, Schuss, Patrick ORCID: 0000-0002-5806-2576, Giordano, Frank A., Radbruch, Alexander, Becker, Albert, Weller, Johannes, Schaub, Christina, Vatter, Hartmut, Schilling, Judith, Winkler, Frank ORCID: 0000-0003-4892-6104, Herrlinger, Ulrich and Schneider, Matthias
(2022).
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Trials, 23 (1).
LONDON:
BMC.
ISSN 1745-6215
von Baumgarten, Louisa, Brucker, David, Tirniceru, Anca, Kienast, Yvonne, Grau, Stefan, Burgold, Steffen, Herms, Jochen and Winkler, Frank ORCID: 0000-0003-4892-6104
(2011).
Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells.
Clin. Cancer Res., 17 (19).
S. 6192 - 6206.
PHILADELPHIA:
AMER ASSOC CANCER RESEARCH.
ISSN 1078-0432